Jazz Pharmaceuticals Closes $1.25B Exchangeable Senior Notes Offering and $225M Share Repurchase
Jazz Pharmaceuticals plc
Subscribe to track JAZZ
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Jazz Pharmaceuticals plc ($JAZZ) closed a $1.25 billion private offering of 1.875% exchangeable senior notes due 2032 (including full option exercise of $150M). Net proceeds are estimated at ~$1,226.4 million for general corporate purposes. Concurrently, the company repurchased ~$225 million of ordinary shares at $249.29 per share.
Comprehensive Analysis
Overview & Summary of Transaction
On August 31, 2026, Jazz Pharmaceuticals plc ($JAZZ) announced the closing of a private offering of $1.25 billion in aggregate principal amount of 1.875% exchangeable senior notes due 2032 by its wholly-owned subsidiary, Jazz Investments I Limited.
Key Terms of the Notes Offering
- Issuer: Jazz Investments I Limited (wholly owned subsidiary)
- Guarantor: Jazz Pharmaceuticals plc (senior unsecured basis)
- Principal Amount: $1.25 billion (includes full exercise of initial purchasers' option for $150 million)
- Coupon / Maturity: 1.875% per year, payable semi-annually on March 15 and September 15, maturing September 15, 2032
- Initial Exchange Rate: 2.8150 ordinary shares per $1,000 principal amount (~$355.24 per ordinary share)
- Net Proceeds: Approximately $1,226.4 million, slated for general corporate purposes
Concurrent Share Repurchase
- Amount Repurchased: Approximately $225.0 million in ordinary shares
- Repurchase Price: $249.29 per share (closing price on August 26, 2026)
- Funding Source: Existing cash on hand under the share repurchase program announced in July 2024
Strategic Impact & Market Significance
The issuance optimizes the company's capital structure with low-cost debt (1.875%) while mitigating equity dilution via a concurrent $225M ordinary share repurchase.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is AI-generated from public SEC filings and may contain errors. It is for informational and educational purposes only and is not investment, legal, or tax advice.
The Filing Fool is not a registered investment adviser, broker-dealer, or financial planner. Nothing here is a recommendation or solicitation to buy, sell, or hold any security.
Always do your own due diligence and consult a licensed professional.